Overview

A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia

Status:
Completed

Trial end date:
2005-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to confirm the efficacy and safety of fludarabine phosphate administered with dose increasing in 6 cycles (1 cycle: 5 treatment days every 28 days) in untreated chronic lymphocytic leukemia (CLL) patients with anemia and/or thrombocytopenia.

Phase:

Phase 4

Details

Lead Sponsor:

Genzyme, a Sanofi Company

Treatments:

Fludarabine
Fludarabine phosphate
Vidarabine